SCHEMBL6764091

SCHEMBL6764091

CN(CC(=O)NCC(=O)O)S(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.53
NFE2L2 Q16236 1/20 0.53
ALDH1A1 P00352 3/20 0.49
POLB P06746 2/20 0.46
LMNA P02545 1/20 0.46
GLA P06280 1/20 0.46
GAA P10253 2/20 0.43
HTT P42858 2/20 0.43
TSHR P16473 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
P2RX7 Q99572 1/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42
MAPT P10636 1/20 0.41
NPY5R Q15761 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11888757 0.85 KEAP1 (0.66) KEAP1NFE2L2ALDH1A1POLBGLA
SCHEMBL6764156 0.82 ALDH1A1 (0.51) ALDH1A1POLBLMNAGLAGAA
SCHEMBL6884912 0.80 MCOLN3 (0.49) ALDH1A1POLBLMNAGLAGAA
SCHEMBL6761747 0.78 RAB9A (0.48) ALDH1A1POLBLMNAGLAGAA
SCHEMBL6763996 0.75 POLB (0.45) ALDH1A1POLBGLAGAAHTT
SCHEMBL5125937 0.74 KEAP1 (0.52) KEAP1NFE2L2LMNAGAACYP2C19
SCHEMBL6767003 0.73 ALDH1A1 (0.50) ALDH1A1POLBLMNAGAAHTT
SCHEMBL14415470 0.73 HTR2A (0.51) KEAP1NFE2L2ALDH1A1HTTCYP2C19
SCHEMBL5316643 0.73 ALDH1A1 (0.64) KEAP1NFE2L2ALDH1A1POLBLMNA
SCHEMBL6762828 0.72 ALDH1A1 (0.59) ALDH1A1POLBLMNAGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB KEAP1 802/4885NFE2L2 1035/4885ALDH1A1 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.